通过ITE激活AHR可以改善肌肉梗塞后老鼠的心脏重塑和功能
Xiaoyan Lin1,2, Weiqiang Liu3,4, Yong Chu3,4
1Department of Echocardiology, Fujian Institute of Hypertension, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
ESC heart failure
|October 6, 2023
概括
亚利碳化合物受体 (AHR) 激动剂ITE通过减少心脏亡和改善心室功能,延迟心肌梗塞 (MI) 后心力衰竭的进展. 这项研究突出了ITE的重点.
科学领域:
- 心血管生物学 心血管生物学
- 药理学 药理学是指药理学的学科.
- 再生医学是一种再生医学.
背景情况:
- 心肌梗塞 (MI) 后的左心室重塑是心力衰竭的主要驱动因素.
- 早期干预用烯碳水化合物受体 (AHR) 激动剂,2-(1'H-英多尔-3'-碳) - 亚-4-碳酸甲基 (ITE),改善心脏功能,但其慢性阶段影响是未知的.
研究的目的:
- 调查ITE在缓解MI后慢性心力衰竭进展方面的治疗潜力.
- 阐明ITE在MI慢性阶段的心脏保护作用背后的分子机制.
主要方法:
- 在老鼠中诱导心肌梗塞,然后用ITE或载体治疗.
- 评估心脏功能和结构使用心声回声学.
- 进行了组织学,生化和分子分析 (包括西式斑点和免疫光),以评估纤维化,炎症,亡和信号通路.
主要成果:
- 在MI小鼠中,ITE治疗显著减轻了心脏重塑,纤维化,炎症和线粒体损伤.
- 通过调节Bcl-2,Bax和分离的caspase-3水平,ITE在剂量依赖下降了心肌细胞亡.
- ITE的使用导致了Akt和p70S6K酸化的下调,表明AHR通路的激活.
结论:
- 该AHR激动剂ITE在MI的慢性阶段显示出显著的心脏保护作用.
- ITE通过Akt/p70S6K信号通路缓解心肌细胞亡,拯救不良的左心室重塑和功能障碍.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
445
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
445
01:25Aortic Regurgitation III: Medical Management
24
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
24